

Summary of Utilization Management (UM) Program Changes

May 2020

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
<i>Actemra</i>	tocilizumab	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> • Trial of a disease-modifying anti-rheumatic drug • Trial of two from the following: Cimzia, Humira, Rinvoq, Simponi/Simponia Aria, Xeljanz/Xeljanz XR <p>Systemic Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> • Trial of a nonsteroidal anti-inflammatory drug or systemic glucocorticoid <p>Polyarticular Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> • Trial of leflunomide or methotrexate • Trial of Humira <p>Giant Cell Arteritis</p> <ul style="list-style-type: none"> • Trial of a glucocorticoid <p>Cytokine Release Syndrome (CRS) Risk due to CAR T-Cell Therapy</p> <ul style="list-style-type: none"> • Receiving or will receive CAR T-cell immunotherapy • Prescribed by or with an oncologist or hematologist 	Update	7/01/2020
<i>Cimzia</i>	certolizumab pegol	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> • Trial of a disease-modifying anti-rheumatic drug <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> • Active disease • Trial of 2 nonsteroidal anti-inflammatory drugs <p>Non-radiographic axial spondylitis</p> <ul style="list-style-type: none"> • Objective signs of inflammation (lab test or MRI) • Trial of 2 nonsteroidal anti-inflammatory drugs • Prescribed by or with a rheumatologist <p>Crohn's Disease</p> <ul style="list-style-type: none"> • Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or methotrexate 	Update	7/01/2020

<i>Cosentyx</i>	secukinumab	<p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> • Active disease • Trial of 2 nonsteroidal anti-inflammatory drugs • Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria • Trial of Taltz <p>Plaque Psoriasis</p> <ul style="list-style-type: none"> • Trial of three from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> • Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara • Trial of Orencia or Xeljanz/Xeljanz XR • Trial of Taltz 	Update	7/01/2020
<i>Enbrel</i>	etanercept	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> • Trial of a disease-modifying anti-rheumatic drug • Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR • Trial of Actemra and Orencia <p>Polyarticular Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> • Trial of leflunomide or methotrexate • Trial of Humira, Actemra, and Orencia <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> • Trial of three from the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara • Trial of two of the following: Taltz, Orencia, Xeljanz/Xeljanz XR <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> • Active disease • Trial of 2 nonsteroidal anti-inflammatory drugs • Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria • Trial of Taltz <p>Plaque Psoriasis</p> <ul style="list-style-type: none"> • For ages 18 and older: Trial of three from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya • Trial of Taltz 	Update	7/01/2020

		<ul style="list-style-type: none"> For ages 12-17: Trial of Stelara 		
<i>Entyvio</i>	vedolizumab	<p>Crohn's Disease</p> <ul style="list-style-type: none"> Trial of two from the following: Humira, infliximab, Cimzia, Stelara <p>Ulcerative Colitis</p> <ul style="list-style-type: none"> Trial of two from the following: Simponi, Humira, infliximab, Stelara 	Update	7/01/2020
<i>Humira</i>	adalimumab	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> Trial of a disease-modifying anti-rheumatic drug <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> Trial of 2 nonsteroidal anti-inflammatory drugs <p>Polyarticular Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> Trial of leflunomide and methotrexate <p>Crohn's Disease</p> <ul style="list-style-type: none"> Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosaliclylate <p>Ulcerative Colitis</p> <ul style="list-style-type: none"> Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosaliclylate 	Update	7/01/2020
<i>Ilumya</i>	tildrakizumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> Trial of three from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya Trial of Taltz 	Update	07/01/2020
<i>Kevzara</i>	sarilumab	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> Trial of a disease-modifying anti-rheumatic drug Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR Trial of Actemra and Oencia 	Update	7/01/2020
<i>Kineret</i>	anakinra	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> Trial of a disease-modifying anti-rheumatic drug Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR Trial of Actemra and Oencia <p>Neonatal-Onset Multisystem Inflammatory Disease (NOMID)</p> <ul style="list-style-type: none"> Diagnosis confirmed by specific genetic mutation 	Update	7/01/2020

		<ul style="list-style-type: none"> Any two of the following symptoms: urticaria-like rash; cold/stress triggered episodes; sensorineural hearing loss; musculoskeletal symptoms; chronic aseptic meningitis; skeletal abnormalities Elevated acute phase reactants (lab test) Prescribed by or with an allergist/immunologist, rheumatologist, or pediatrician <p>Systemic Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> Prescribed by or with a rheumatologist Trial of a nonsteroidal anti-inflammatory drug or systemic glucocorticoid 		
<i>Olumiant</i>	baricitinib	<p>Rheumatoid arthritis</p> <ul style="list-style-type: none"> Moderate to severe disease Trial of a disease-modifying anti-rheumatic drug Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR Trial of Actemra and Orencia Prescribed by or with a rheumatologist Not also receiving a strong immunosuppressant 	New	7/01/2020
<i>Orencia</i>	abatacept	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> Trial of a disease-modifying anti-rheumatic drug Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Rinvoq, Xeljanz/Xeljanz XR <p>Juvenile Idiopathic Arthritis</p> <ul style="list-style-type: none"> Trial of leflunomide or methotrexate Trial of Humira <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> Trial of two from the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara 	Update	7/01/2020
<i>Otezla</i>	apremilast	<p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> No prior drug therapy trials required <p>Plaque Psoriasis</p> <ul style="list-style-type: none"> One of the following: greater than 10% body surface area, 	Update	7/01/2020

		<p>palmoplantar involvement, or severe scalp psoriasis</p> <ul style="list-style-type: none"> No prior drug therapy trials required 		
<i>Rinvoq</i>	upadacitinib	<p>Rheumatoid arthritis</p> <ul style="list-style-type: none"> Moderate to severe disease Trial of a disease-modifying anti-rheumatic drug Prescribed by or with a rheumatologist Not also receiving a strong immunosuppressant 	New	7/01/2020
<i>Siliq</i>	brodalumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> No prior oral or topical drug therapy or phototherapy required Trial of three from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya Trial of Taltz 	Update	7/01/2020
<i>Simponi/Simponi Aria</i>	golimumab	<p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> Trial of or is currently taking methotrexate <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> Active disease No prior therapy required <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> Active disease Trial of 2 nonsteroidal anti-inflammatory drugs <p>Ulcerative Colitis</p> <ul style="list-style-type: none"> Corticosteroid dependent OR Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosalicylate 	Update	7/01/2020
<i>Skyrizi</i>	risankizumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> Moderate to severe disease Prescribed by or with dermatology 	New	7/01/2020
<i>Stelara</i>	ustekinumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> No prior oral or topical drug therapy or phototherapy required No prior biologic therapy required <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> For 45 mg dose: active disease No prior therapy required For 90 mg dose: active disease with co-existing moderate to severe psoriasis 	Update	7/01/2020

		<ul style="list-style-type: none"> No prior therapy required Weight > 220 pounds <p>Crohn's Disease</p> <ul style="list-style-type: none"> Trial of at least one tumor necrosis factor (TNF) blocker OR Trial of at least one oral immunomodulator or corticosteroid Intravenous dose: based on weight per FDA-approved doses <p>Ulcerative Colitis</p> <ul style="list-style-type: none"> Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosalicylate OR Trial of at least one biologic agent (Entyvio or tumor necrosis factor (TNF) blocker) Intravenous dose: based on weight per FDA-approved doses 		
<i>Taltz</i>	ixekizumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> No prior oral or topical drug therapy or phototherapy required Trial of one from the following: Cimzia, Humira, Skyrizi, Stelara, Tremfya <p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> Trial of one of the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara <p>Ankylosing Spondylitis</p> <ul style="list-style-type: none"> Active disease Trial of 2 nonsteroidal anti-inflammatory drugs Trial of one of the following: Cimzia, Humira, Simponi/Simponi Aria 	Update	7/01/2020
<i>Tremfya</i>	guselkumab	<p>Plaque Psoriasis</p> <ul style="list-style-type: none"> No prior oral or topical drug therapy or phototherapy required 	Update	7/01/2020
<i>Xeljanz/Xeljanz XR</i>	tofacitinib	<p>Psoriatic Arthritis</p> <ul style="list-style-type: none"> Trial of a disease-modifying anti-rheumatic drug Trial of 2 of the following: Cimzia, Humira, Simponi/Simponi Aria, Stelara OR Documented needle phobia <p>Rheumatoid Arthritis</p> <ul style="list-style-type: none"> Trial of a disease-modifying anti-rheumatic drug 	Update	7/01/2020

		<p>Ulcerative Colitis</p> <ul style="list-style-type: none">• Trial of 6-mercaptopurine, azathioprine, a corticosteroid, or an aminosalicylate OR• Trial of 2 of the following: Humira, infliximab, Simponi, Stelara OR• Documented needle phobia		
--	--	---	--	--